Aptorum Group Limited (NASDAQ:APM) Sees Significant Growth in Short Interest

Aptorum Group Limited (NASDAQ:APM) was the target of a large increase in short interest during the month of February. As of February 27th, there was short interest totaling 11,553 shares, an increase of 14.8% from the February 12th total of 10,060 shares. Approximately 0.5% of the company’s shares are sold short. Based on an average daily trading volume, of 12,784 shares, the short-interest ratio is currently 0.9 days. Based on an average daily trading volume, of 12,784 shares, the short-interest ratio is currently 0.9 days. Approximately 0.5% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Aptorum Group in a research report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Aptorum Group Trading Down 0.4%

Aptorum Group stock opened at $0.78 on Wednesday. The stock has a fifty day moving average price of $0.87 and a two-hundred day moving average price of $1.30. Aptorum Group has a 52-week low of $0.65 and a 52-week high of $4.47.

About Aptorum Group

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.